JP2023123726A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023123726A5 JP2023123726A5 JP2023105929A JP2023105929A JP2023123726A5 JP 2023123726 A5 JP2023123726 A5 JP 2023123726A5 JP 2023105929 A JP2023105929 A JP 2023105929A JP 2023105929 A JP2023105929 A JP 2023105929A JP 2023123726 A5 JP2023123726 A5 JP 2023123726A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- hvr
- amino acid
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017091955 | 2017-05-02 | ||
| JP2017091955 | 2017-05-02 | ||
| PCT/JP2018/017495 WO2018203567A1 (en) | 2017-05-02 | 2018-05-02 | Cytotoxicity-inducing therapeutic agent |
| JP2019559378A JP2020518584A (ja) | 2017-05-02 | 2018-05-02 | 細胞傷害誘導治療剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559378A Division JP2020518584A (ja) | 2017-05-02 | 2018-05-02 | 細胞傷害誘導治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023123726A JP2023123726A (ja) | 2023-09-05 |
| JP2023123726A5 true JP2023123726A5 (enExample) | 2025-08-05 |
Family
ID=64016153
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559378A Pending JP2020518584A (ja) | 2017-05-02 | 2018-05-02 | 細胞傷害誘導治療剤 |
| JP2023105929A Pending JP2023123726A (ja) | 2017-05-02 | 2023-06-28 | 細胞傷害誘導治療剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559378A Pending JP2020518584A (ja) | 2017-05-02 | 2018-05-02 | 細胞傷害誘導治療剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20200123256A1 (enExample) |
| EP (1) | EP3619238A4 (enExample) |
| JP (2) | JP2020518584A (enExample) |
| WO (1) | WO2018203567A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG190726A1 (en) | 2010-11-30 | 2013-07-31 | Chugai Pharmaceutical Co Ltd | Cytotoxicity-inducing therapeutic agent |
| KR102398736B1 (ko) | 2011-10-31 | 2022-05-16 | 추가이 세이야쿠 가부시키가이샤 | 중쇄와 경쇄의 회합이 제어된 항원 결합 분자 |
| WO2015156268A1 (ja) | 2014-04-07 | 2015-10-15 | 中外製薬株式会社 | 免疫活性化抗原結合分子 |
| CN106459954A (zh) | 2014-05-13 | 2017-02-22 | 中外制药株式会社 | 用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子 |
| US11660340B2 (en) | 2015-11-18 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function |
| JP6925278B2 (ja) | 2015-11-18 | 2021-08-25 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
| EP3398965A4 (en) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PROMOTING THE EFFICIENCY OF CLEANING POLYPEPTIDE WITH FC REGION |
| JP7617603B2 (ja) | 2017-01-11 | 2025-01-20 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｒ－スポンジン（ｒｓｐｏ）サロゲート分子 |
| CA3050133A1 (en) | 2017-01-26 | 2018-08-02 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
| EP3820499A4 (en) | 2018-07-09 | 2022-07-13 | Surrozen Operating, Inc. | TISSUE SPECIFIC WNT SIGNAL ENHANCEMENT MOLECULES AND USES |
| US12454580B2 (en) | 2020-04-10 | 2025-10-28 | Regeneron Pharmaceuticals, Inc. | FRB antibodies |
| CN112175080B (zh) * | 2020-10-22 | 2021-05-25 | 优睿赛思(武汉)生物科技有限公司 | 抗人白介素-6高亲和力兔单克隆抗体及应用 |
| WO2022104280A1 (en) | 2020-11-16 | 2022-05-19 | Surrozen Operating, Inc. | Liver-specific wnt signal enhancing molecules and uses thereof |
| EP4288458A1 (en) * | 2021-02-03 | 2023-12-13 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
| WO2023164277A2 (en) * | 2022-02-28 | 2023-08-31 | Adept Therapeutics Inc. | Anti-programmed death-ligand 1 (pd-l1) antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6449295B2 (ja) * | 2013-12-17 | 2019-01-09 | ジェネンテック， インコーポレイテッド | 抗ｃｄ３抗体および使用方法 |
| EP3134121A4 (en) * | 2014-04-21 | 2017-11-08 | Abbvie Stemcentrx LLC | Novel anti-rnf43 antibodies and methods of use |
| MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| HK1252158A1 (zh) * | 2015-05-01 | 2019-05-17 | Genentech, Inc. | 掩蔽抗cd3抗体和使用方法 |
-
2018
- 2018-05-02 JP JP2019559378A patent/JP2020518584A/ja active Pending
- 2018-05-02 WO PCT/JP2018/017495 patent/WO2018203567A1/en not_active Ceased
- 2018-05-02 EP EP18794608.2A patent/EP3619238A4/en active Pending
- 2018-05-02 US US16/605,556 patent/US20200123256A1/en not_active Abandoned
-
2023
- 2023-06-28 JP JP2023105929A patent/JP2023123726A/ja active Pending
- 2023-12-11 US US18/535,310 patent/US20240239890A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023123726A5 (enExample) | ||
| JP2019502712A5 (enExample) | ||
| JP2022031635A5 (enExample) | ||
| JP2020180158A5 (enExample) | ||
| JP2018522541A5 (enExample) | ||
| JP2023134618A5 (enExample) | ||
| CN115702008A (zh) | 抗体药物偶联物 | |
| JP2018108081A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| JP2017534577A5 (enExample) | ||
| JP2023116744A5 (enExample) | ||
| JP2019513701A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2018527887A5 (enExample) | ||
| FI4141032T3 (fi) | T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito | |
| HRP20240939T1 (hr) | Anti-cd3 protutijela i metode uporabe | |
| JP2020502233A5 (enExample) | ||
| JPWO2019204564A5 (enExample) | ||
| JPWO2018206790A5 (enExample) | ||
| JPWO2022044573A5 (enExample) | ||
| JP2023103352A5 (enExample) | ||
| JPWO2020033664A5 (enExample) | ||
| IL277899B2 (en) | Methods and preparations for treating yellow fever | |
| JPWO2019201959A5 (enExample) |